Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCI / HK Connect Inclusion (Mar 2026): Lessons from a Sep 2025 Retrospective Event Study

HK Connect March 2026: Implementation Forecast and Positioning Framework

HSCI / HK Connect (March 2026): Implementation Today & Positioning

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Event-Driven

<ul>
<li>We identify stocks likely to be added to the Hang Seng Composite Index in the upcoming review and, in turn, become eligible for Hong Kong Stock Connect.</li>
<li>Using market cap, free float and liquidity screens, we compile a preliminary list of potential inclusion candidates ahead of the review cut-off.</li>
<li>A follow-up note will focus on which inclusion candidates are most likely to translate eligibility into actionable trading opportunities.</li>
</ul>


We identify stocks likely to be added to the Hang Seng Composite Index in the upcoming review and, in turn, become eligible for Hong Kong Stock Connect.
Using market cap, free float and liquidity screens, we compile a preliminary list of potential inclusion candidates ahead of the review cut-off.
A follow-up note will focus on which inclusion candidates are most likely to translate eligibility into actionable trading opportunities.


Suzhou Novosense Microelectronics (2676 HK)

HSCI / Hong Kong Connect Inclusion (March 2026): A Preliminary Assessment

Pony AI

HSCI / Hong Kong Connect Inclusion (March 2026): A Preliminary Assessment